CCND1 and FGFR1 gene amplifications are associated with reduced benefit from aromatase inhibitors in metastatic breast cancer.

Autor: Aleksakhina SN; Laboratory of Molecular Oncology, N.N. Petrov Institute of Oncology, Saint-Petersburg, Russia, 197758., Kramchaninov MM; City Cancer Center, Saint-Petersburg, Russia, 197758., Mikushina AD; Laboratory of Molecular Oncology, N.N. Petrov Institute of Oncology, Saint-Petersburg, Russia, 197758., Kubrina SE; Laboratory of Molecular Oncology, N.N. Petrov Institute of Oncology, Saint-Petersburg, Russia, 197758., Petkau VV; Sverdlovskiy Regional Oncological Hospital, Ekatherinburg, Russia, 620036., Ivantsov AO; Laboratory of Molecular Oncology, N.N. Petrov Institute of Oncology, Saint-Petersburg, Russia, 197758., Moiseyenko VM; City Cancer Center, Saint-Petersburg, Russia, 197758., Imyanitov EN; Laboratory of Molecular Oncology, N.N. Petrov Institute of Oncology, Saint-Petersburg, Russia, 197758.; Saint-Petersburg Pediatric Medical University, Saint-Petersburg, Russia, 194100.; I.I. Mechnikov North-Western Medical University, Saint-Petersburg, Russia, 191015., Iyevleva AG; Laboratory of Molecular Oncology, N.N. Petrov Institute of Oncology, Saint-Petersburg, Russia, 197758. aglayai@inbox.ru.; Saint-Petersburg Pediatric Medical University, Saint-Petersburg, Russia, 194100. aglayai@inbox.ru.

Publikováno v: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico [Clin Transl Oncol] 2021 Apr; Vol. 23 (4), pp. 874-881. Date of Electronic Publication: 2020 Sep 02.

First-Line Cetuximab Monotherapy in KRAS/NRAS/BRAF Mutation-Negative Colorectal Cancer Patients.

Autor: Moiseyenko VM; City Cancer Center, Saint Petersburg, 197758, Russia., Moiseyenko FV; City Cancer Center, Saint Petersburg, 197758, Russia.; Laboratory of Molecular Oncology, N.N. Petrov Institute of Oncology, Pesochny-2, Saint Petersburg, 197758, Russia.; I.I. Mechnikov North-Western Medical University, Saint Petersburg, 191015, Russia., Yanus GA; Laboratory of Molecular Oncology, N.N. Petrov Institute of Oncology, Pesochny-2, Saint Petersburg, 197758, Russia.; St. Petersburg Pediatric Medical University, Saint Petersburg, 194100, Russia., Kuligina ES; Laboratory of Molecular Oncology, N.N. Petrov Institute of Oncology, Pesochny-2, Saint Petersburg, 197758, Russia., Sokolenko AP; Laboratory of Molecular Oncology, N.N. Petrov Institute of Oncology, Pesochny-2, Saint Petersburg, 197758, Russia.; St. Petersburg Pediatric Medical University, Saint Petersburg, 194100, Russia., Bizin IV; St. Petersburg State Polytechnical University, Saint Petersburg, 195251, Russia., Kudriavtsev AA; City Cancer Center, Saint Petersburg, 197758, Russia., Aleksakhina SN; Laboratory of Molecular Oncology, N.N. Petrov Institute of Oncology, Pesochny-2, Saint Petersburg, 197758, Russia., Volkov NM; City Cancer Center, Saint Petersburg, 197758, Russia., Chubenko VA; City Cancer Center, Saint Petersburg, 197758, Russia., Kozyreva KS; City Cancer Center, Saint Petersburg, 197758, Russia., Kramchaninov MM; City Cancer Center, Saint Petersburg, 197758, Russia.; St. Petersburg Pediatric Medical University, Saint Petersburg, 194100, Russia., Zhuravlev AS; City Cancer Center, Saint Petersburg, 197758, Russia., Shelekhova KV; City Cancer Center, Saint Petersburg, 197758, Russia., Pashkov DV; S.M. Kirov Military Medical Academy, Saint Petersburg, 194044, Russia., Ivantsov AO; Laboratory of Molecular Oncology, N.N. Petrov Institute of Oncology, Pesochny-2, Saint Petersburg, 197758, Russia.; St. Petersburg Pediatric Medical University, Saint Petersburg, 194100, Russia., Venina AR; Laboratory of Molecular Oncology, N.N. Petrov Institute of Oncology, Pesochny-2, Saint Petersburg, 197758, Russia., Sokolova TN; Laboratory of Molecular Oncology, N.N. Petrov Institute of Oncology, Pesochny-2, Saint Petersburg, 197758, Russia., Preobrazhenskaya EV; Laboratory of Molecular Oncology, N.N. Petrov Institute of Oncology, Pesochny-2, Saint Petersburg, 197758, Russia.; St. Petersburg Pediatric Medical University, Saint Petersburg, 194100, Russia., Mitiushkina NV; Laboratory of Molecular Oncology, N.N. Petrov Institute of Oncology, Pesochny-2, Saint Petersburg, 197758, Russia., Togo AV; Laboratory of Molecular Oncology, N.N. Petrov Institute of Oncology, Pesochny-2, Saint Petersburg, 197758, Russia.; St. Petersburg Pediatric Medical University, Saint Petersburg, 194100, Russia., Iyevleva AG; Laboratory of Molecular Oncology, N.N. Petrov Institute of Oncology, Pesochny-2, Saint Petersburg, 197758, Russia.; St. Petersburg Pediatric Medical University, Saint Petersburg, 194100, Russia., Imyanitov EN; City Cancer Center, Saint Petersburg, 197758, Russia. evgeny@imyanitov.spb.ru.; Laboratory of Molecular Oncology, N.N. Petrov Institute of Oncology, Pesochny-2, Saint Petersburg, 197758, Russia. evgeny@imyanitov.spb.ru.; I.I. Mechnikov North-Western Medical University, Saint Petersburg, 191015, Russia. evgeny@imyanitov.spb.ru.; St. Petersburg Pediatric Medical University, Saint Petersburg, 194100, Russia. evgeny@imyanitov.spb.ru.; St. Petersburg State University, Saint Petersburg, 199034, Russia. evgeny@imyanitov.spb.ru.

Publikováno v: Clinical drug investigation [Clin Drug Investig] 2018 Jun; Vol. 38 (6), pp. 553-562.

[Experience with the use of gefitinib in patients with inoperable non-squamous cell lung cancer with activating EGFR mutations].

Autor: Moiseenko VM, Chubenko VA, Moiseenko FV, Ivantsov AO, Kramchaninov MM, Imyanitov EN

Publikováno v: Voprosy onkologii [Vopr Onkol] 2015; Vol. 61 (2), pp. 259-65.